Who We Are

The CSL Behring story spans decades of innovation, collaboration, patient focus, and an ongoing drive for excellence.

Product Overview

CSL Behring develops, manufactures and markets protein based therapies, including:

Pulmonary Therapies

Features

Policy Impact Newsletters

Public Policy Report for Europe covers Compassionate Access, PID Recommendations and HTAs

Personal Stories

Entrepreneur with
Hemophilia Focuses
on his Goals

Key Issues Dialogue

Access to Care: Barriers and Possible Solutions Examined

News

12-Jan-2012
First Trial Site Initiated in Phase II/III Study of rIX-FP

03-Jan-2012
FDA Approves Label Expansion for Self-administration of Berinert®

02-Dec-2011
LEAD Grant Awarded to American Plasma Users Coalition

08-Nov-2011
Life Sciences Company of the Year

05-Nov-2011
C1-INH Concentrate Effective in Acute Attacks of HAE in Children